Preclinical investigation of CuATSM treatment (30–200 mg/kg/day) in numerous SOD1 ALS mouse models has demonstrated the ability of CuATSM to significantly delay the onset of ALS symptoms, reduce weight loss and extend lifespan (Table 1), with no reported adverse side effects attributed to CuATSM treatment. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.